<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39195986</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-0590</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature cardiovascular research</Title><ISOAbbreviation>Nat Cardiovasc Res</ISOAbbreviation></Journal><ArticleTitle>The pathological maelstrom of COVID-19 and cardiovascular disease.</ArticleTitle><Pagination><StartPage>200</StartPage><EndPage>210</EndPage><MedlinePgn>200-210</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s44161-022-00029-5</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) is a consequence of infection of the upper and lower respiratory tract with severe acute respiratory syndrome coronavirus 2 but often becomes a systemic disease, with important involvement of other organs. A bidirectional relationship exists between COVID-19 and cardiovascular disease. On the one hand, preexisting comorbidities, in particular high prevalence of cardiovascular risk factors such as hypertension and diabetes and chronic cardiovascular conditions predispose to severe disease. On the other hand, biomarkers of myocardial injury are frequently raised in patients with COVID-19, along with arrhythmia and heart failure. Localized thrombosis is a common finding in the lungs but can also increase the occurrence of thrombotic events systemically. Thrombosis is consequent to different pathogenic mechanisms, which include endothelial dysfunction and immunothrombosis. Thrombocytopenia is common in patients with COVID-19 and alterations in platelet function participate in the pro-thrombotic phenotype. Involvement of the cardiovascular system in COVID-19 has important consequences during recovery from infection and the development of long COVID.</AbstractText><CopyrightInformation>&#xa9; 2022. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giacca</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2927-7225</Identifier><AffiliationInfo><Affiliation>King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine &amp; Sciences, London, UK. mauro.giacca@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Ajay M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6547-0631</Identifier><AffiliationInfo><Affiliation>King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine &amp; Sciences, London, UK. ajay.shah@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>787971</GrantID><Agency>EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013))</Agency><Country/></Grant><Grant><GrantID>RG/19/11/34633</GrantID><Agency>British Heart Foundation (BHF)</Agency><Country/></Grant><Grant><GrantID>CH/1999001/11735</GrantID><Agency>British Heart Foundation (BHF)</Agency><Country/></Grant><Grant><GrantID>RE/18/2/34213</GrantID><Agency>British Heart Foundation (BHF)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cardiovasc Res</MedlineTA><NlmUniqueID>9918284280206676</NlmUniqueID><ISSNLinking>2731-0590</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39195986</ArticleId><ArticleId IdType="doi">10.1038/s44161-022-00029-5</ArticleId><ArticleId IdType="pii">10.1038/s44161-022-00029-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang, J. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 94, 91&#x2013;95 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32173574</ArticleId><ArticleId IdType="pmc">7194638</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2020.03.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty, A. B. et al. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 369, m1985 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32444460</ArticleId><ArticleId IdType="pmc">7243036</ArticleId><ArticleId IdType="doi">10.1136/bmj.m1985</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson, S. et al. Presenting characteristics, comorbidities and outcomes among 5,700 patients hospitalized with COVID-19 in the New York City area. JAMA 323, 2052&#x2013;2059 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId><ArticleId IdType="pmc">7177629</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.6775</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430&#x2013;436 (2020). Retrospective analysis of over 17,000 primary care records, of which almost 11,000 linked to COVID-19-related deaths from the OpenSAFELY database generated on behalf of NHS England, to examine factors associated with COVID-19-related deaths.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640463</ArticleId><ArticleId IdType="pmc">7611074</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Z. &amp; McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323, 1239&#x2013;1242 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId></ArticleIdList></Reference><Reference><Citation>Inciardi, R. M. et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur. Heart J. 41, 1821&#x2013;1829 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32383763</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaa388</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman, N. et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 8, 823&#x2013;833 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32798471</ArticleId><ArticleId IdType="pmc">7426091</ArticleId><ArticleId IdType="doi">10.1016/S2213-8587(20)30271-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouwels, K. B. et al. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public Health 6, e30&#x2013;e38 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33308423</ArticleId><ArticleId IdType="doi">10.1016/S2468-2667(20)30282-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuille-dit-Bille, R. N. et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE inhibitors. Amino Acids 47, 693&#x2013;705 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25534429</ArticleId><ArticleId IdType="doi">10.1007/s00726-014-1889-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Bean, D. M. et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multisite UK acute hospital trust. Eur. J. Heart Fail. 22, 967&#x2013;974 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32485082</ArticleId><ArticleId IdType="doi">10.1002/ejhf.1924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox, J. et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart 106, 1503&#x2013;1511 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32737124</ArticleId><ArticleId IdType="doi">10.1136/heartjnl-2020-317393</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia, G., Rea, F., Ludergnani, M., Apolone, G. &amp; Corrao, G. Renin&#x2013;angiotensin&#x2013;aldosterone system blockers and the risk of COVID-19. N. Engl. J. Med. 382, 2431&#x2013;2440 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32356627</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2006923</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales, D. R. et al. Renin&#x2013;angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit. Health 3, e98&#x2013;e114 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33342753</ArticleId><ArticleId IdType="doi">10.1016/S2589-7500(20)30289-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivula, I., Sten, M. &amp; Makela, P. H. Risk factors for pneumonia in the elderly. Am. J. Med. 96, 313&#x2013;320 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8166149</ArticleId><ArticleId IdType="doi">10.1016/0002-9343(94)90060-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias-Fernandez, L., Gil-Prieto, R. &amp; Gil-de-Miguel, A. Incidence, mortality and lethality of hospitalizations for community-acquired pneumonia with comorbid cardiovascular disease in Spain (1997&#x2013;2015). BMC Infect. Dis. 20, 477 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32631257</ArticleId><ArticleId IdType="pmc">7336298</ArticleId><ArticleId IdType="doi">10.1186/s12879-020-05208-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, S. X. et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat. Rev. Cardiol. 18, 194&#x2013;209 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33214651</ArticleId><ArticleId IdType="doi">10.1038/s41569-020-00469-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb Hooper, M., Napoles, A. M. &amp; Perez-Stable, E. J. COVID-19 and racial/ethnic disparities. JAMA 323, 2466&#x2013;2467 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32391864</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.8598</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaca-Mandic, P., Georgiou, A. &amp; Sen, S. Assessment of COVID-19 hospitalizations by race/ethnicity in 12 states. JAMA Intern. Med. 181, 131&#x2013;134 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32804192</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2020.3857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, H. Q. et al. The contribution of multiple long-term conditions to widening inequalities in disability-free life expectancy over two decades: longitudinal analysis of two cohorts using the Cognitive Function and Ageing Studies. EClinicalMedicine 39, 101041 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34386756</ArticleId><ArticleId IdType="pmc">8342913</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2021.101041</ArticleId></ArticleIdList></Reference><Reference><Citation>Nafilyan, V. et al. Ethnic differences in COVID-19 mortality during the first two waves of the coronavirus pandemic: a nationwide cohort study of 29 million adults in England. Eur. J. Epidemiol. 36, 605&#x2013;617 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34132940</ArticleId><ArticleId IdType="pmc">8206182</ArticleId><ArticleId IdType="doi">10.1007/s10654-021-00765-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman, J. M. &amp; Bassett, M. T. Variation in COVID-19 mortality in the US by race and ethnicity and educational attainment. JAMA Netw. Open 4, e2135967 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34812846</ArticleId><ArticleId IdType="pmc">8611482</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.35967</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur, R. et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet 397, 1711&#x2013;1724 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33939953</ArticleId><ArticleId IdType="pmc">8087292</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)00634-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakeri, R. et al. A case&#x2013;control and cohort study to determine the relationship between ethnic background and severe COVID-19. EClinicalMedicine 28, 100574 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33052324</ArticleId><ArticleId IdType="pmc">7545271</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2020.100574</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancati, F. L., Kao, W. H., Folsom, A. R., Watson, R. L. &amp; Szklo, M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 283, 2253&#x2013;2259 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10807384</ArticleId><ArticleId IdType="doi">10.1001/jama.283.17.2253</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillin, T., Forouhi, N. G., McKeigue, P. M., Chaturvedi, N. &amp; Group, S. S. Southall And Brent REvisited: cohort profile of SABRE, a UK population-based comparison of cardiovascular disease and diabetes in people of European, Indian Asian and African Caribbean origins. Int. J. Epidemiol. 41, 33&#x2013;42 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21044979</ArticleId><ArticleId IdType="doi">10.1093/ije/dyq175</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, A. P., Wang, M., Kartoun, U., Ng, K. &amp; Khera, A. V. Quantifying and understanding the higher risk of atherosclerotic cardiovascular disease among South Asian individuals: results from the UK Biobank Prospective Cohort Study. Circulation 144, 410&#x2013;422 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34247495</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.052430</ArticleId></ArticleIdList></Reference><Reference><Citation>Argenziano, M. G. et al. Characterization and clinical course of 1,000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 369, m1996 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32471884</ArticleId><ArticleId IdType="pmc">7256651</ArticleId><ArticleId IdType="doi">10.1136/bmj.m1996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lala, A. et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J. Am. Coll. Cardiol. 76, 533&#x2013;546 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32517963</ArticleId><ArticleId IdType="pmc">7279721</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2020.06.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Stals, M. et al. Risk of thrombotic complications in influenza versus COVID-19-hospitalized patients. Res. Pract. Thromb. Haemost. https://doi.org/10.1002/rth2.12496 (2021).</Citation></Reference><Reference><Citation>Bangalore, S. et al. ST-segment elevation in patients with COVID-19&#x2014;a case series. N. Engl. J. Med. 382, 2478&#x2013;2480 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32302081</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2009020</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis, I., Fonseca-Rodriguez, O., Farrington, P., Lindmark, K. &amp; Fors Connolly, A. M. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 398, 599&#x2013;607 (2021). Population-based epidemiological study in over 86,000 patients with COVID-19 in Sweden showing a significantly increased risk for acute myocardial infarction and ischemic stroke.</Citation><ArticleIdList><ArticleId IdType="pubmed">34332652</ArticleId><ArticleId IdType="pmc">8321431</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)00896-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, S. et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur. Heart J. 41, 2070&#x2013;2079 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32391877</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaa408</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, S. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 5, 802&#x2013;810 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32211816</ArticleId><ArticleId IdType="pmc">7097841</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5, 811&#x2013;818 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32219356</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammann, P. et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J. Am. Coll. Cardiol. 41, 2004&#x2013;2009 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12798573</ArticleId><ArticleId IdType="doi">10.1016/S0735-1097(03)00421-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajwa, E. K. et al. Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome. Crit. Care Med. 35, 2484&#x2013;2490 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18084839</ArticleId><ArticleId IdType="doi">10.1097/01.CCM.0000281852.36573.22</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirak, P. et al. Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study. ESC Heart Fail. 8, 37&#x2013;46 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33350605</ArticleId><ArticleId IdType="doi">10.1002/ehf2.13136</ArticleId></ArticleIdList></Reference><Reference><Citation>Dweck, M. R. et al. Global evaluation of echocardiography in patients with COVID-19. Eur. Heart J. Cardiovasc. Imaging 21, 949&#x2013;958 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32556199</ArticleId><ArticleId IdType="pmc">7337658</ArticleId><ArticleId IdType="doi">10.1093/ehjci/jeaa178</ArticleId></ArticleIdList></Reference><Reference><Citation>Karagodin, I. et al. Echocardiographic correlates of in-hospital death in patients with acute COVID-19 infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study. J. Am. Soc. Echocardiogr. 34, 819&#x2013;830 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34023454</ArticleId><ArticleId IdType="pmc">8137346</ArticleId><ArticleId IdType="doi">10.1016/j.echo.2021.05.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekely, Y. et al. Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study. Circulation 142, 342&#x2013;353 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32469253</ArticleId><ArticleId IdType="pmc">7382541</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047971</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, H. et al. Reduced first-phase ejection fraction and sustained myocardial wall stress in hypertensive patients with diastolic dysfunction: a manifestation of impaired shortening deactivation that links systolic to diastolic dysfunction and preserves systolic ejection fraction. Hypertension 69, 633&#x2013;640 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28223475</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.116.08545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, H. et al. First-phase ejection fraction, a measure of preclinical heart failure, is strongly associated with increased mortality in patients with COVID-19. Hypertension 77, 2014&#x2013;2022 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33966447</ArticleId><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.121.17099</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Gallagher, K. et al. preexisting cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19. BMC Cardiovasc. Disord. 21, 327 (2021). Results from a cohort study of more than 1,700 consecutive adults hospitalized for severe COVID-19 in the United Kingdom showing that preexisting established cardiovascular disease is a more important contributor to mortality than cardiovascular risk factors in the absence of cardiovascular disease.</Citation><ArticleIdList><ArticleId IdType="pubmed">34217220</ArticleId><ArticleId IdType="pmc">8254437</ArticleId><ArticleId IdType="doi">10.1186/s12872-021-02137-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen, S. E. et al. Cardiovascular magnetic resonance for patients with COVID-19. JACC Cardiovasc. Imaging https://doi.org/10.1016/j.jcmg.2021.08.021 (2021).</Citation></Reference><Reference><Citation>Chen, B. H. et al. Early cardiac involvement in patients with acute COVID-19 infection identified by multiparametric cardiovascular magnetic resonance imaging. Eur. Heart J. Cardiovasc. Imaging 22, 844&#x2013;851 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33686389</ArticleId><ArticleId IdType="doi">10.1093/ehjci/jeab042</ArticleId></ArticleIdList></Reference><Reference><Citation>Raisi-Estabragh, Z. et al. Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank. Aging Clin. Exp. Res. 33, 1133&#x2013;1144 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33683678</ArticleId><ArticleId IdType="pmc">7938275</ArticleId><ArticleId IdType="doi">10.1007/s40520-021-01808-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann, V. O. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5, 1265&#x2013;1273 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32730619</ArticleId><ArticleId IdType="pmc">7385689</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotecha, T. et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur. Heart J. 42, 1866&#x2013;1878 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33596594</ArticleId><ArticleId IdType="pmc">7928984</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehab075</ArticleId></ArticleIdList></Reference><Reference><Citation>Joy, G. et al. Prospective case&#x2013;control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Cardiovasc. Imaging https://doi.org/10.1016/j.jcmg.2021.04.011 (2021).</Citation></Reference><Reference><Citation>Raman, B. et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine 31, 100683 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33490928</ArticleId><ArticleId IdType="pmc">7808914</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2020.100683</ArticleId></ArticleIdList></Reference><Reference><Citation>Brault, C. et al. COVID-19- versus non-COVID-19-related acute respiratory distress syndrome: differences and similarities. Am. J. Respir. Crit. Care Med. 202, 1301&#x2013;1304 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32857595</ArticleId><ArticleId IdType="pmc">7605202</ArticleId><ArticleId IdType="doi">10.1164/rccm.202005-2025LE</ArticleId></ArticleIdList></Reference><Reference><Citation>Norderfeldt, J. et al. Acute pulmonary hypertension and short-term outcomes in severe COVID-19 patients needing intensive care. Acta Anaesthesiol. Scand. 65, 761&#x2013;769 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33728633</ArticleId><ArticleId IdType="pmc">8250592</ArticleId><ArticleId IdType="doi">10.1111/aas.13819</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzur-Sandoval, D. et al. Right ventricular dysfunction and right ventricular-arterial uncoupling at admission increase the in-hospital mortality in patients with COVID-19 disease. Echocardiography 38, 1345&#x2013;1351 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34286870</ArticleId><ArticleId IdType="pmc">8444818</ArticleId></ArticleIdList></Reference><Reference><Citation>Caravita, S. et al. Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization. Eur. J. Heart Fail. 22, 2228&#x2013;2237 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33200458</ArticleId><ArticleId IdType="doi">10.1002/ejhf.2058</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu, H. et al. First-phase ejection fraction is a powerful predictor of adverse events in asymptomatic patients with aortic stenosis and preserved total ejection fraction. JACC Cardiovasc. Imaging 12, 52&#x2013;63 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30448118</ArticleId><ArticleId IdType="doi">10.1016/j.jcmg.2018.08.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Halushka, M. K. &amp; Vander Heide, R. S. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc. Pathol. 50, 107300 (2021). Meta-analysis of 22 different postmortem studies showing that secondary or preexisting myocardial abnormalities are common in patients with COVID-19, whereas myocarditis is rare.</Citation><ArticleIdList><ArticleId IdType="pubmed">33132119</ArticleId><ArticleId IdType="doi">10.1016/j.carpath.2020.107300</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Ferro, M. et al. SARS-CoV-2, myocardial injury and inflammation: insights from a large clinical and autopsy study. Clin. Res. Cardiol. 110, 1822&#x2013;1831 (2021).</Citation></Reference><Reference><Citation>Lindner, D. et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiol. 5, 1281&#x2013;1285 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32730555</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2020.3551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bois, M. C. et al. COVID-19-associated nonocclusive fibrin microthrombi in the heart. Circulation 143, 230&#x2013;243 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33197204</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050754</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini, D. et al. Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study. Circulation 143, 1031&#x2013;1042 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33480806</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.051828</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, J. E. et al. COVID coronary vascular thrombosis: correlation with neutrophil but not endothelial activation. Am. J. Pathol. 192, 112&#x2013;120 (2021).</Citation></Reference><Reference><Citation>Nicin, L. et al. Cell-type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur. Heart J. 41, 1804&#x2013;1806 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32293672</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaa311</ArticleId></ArticleIdList></Reference><Reference><Citation>Navaratnarajah, C. K. et al. Highly efficient SARS-CoV-2 infection of human cardiomyocytes: spike protein-mediated cell fusion and its inhibition. J. Virol. 95, e0136821 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34613786</ArticleId><ArticleId IdType="doi">10.1128/JVI.01368-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, A. et al. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep. Med. 1, 100052 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32835305</ArticleId><ArticleId IdType="pmc">7323681</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2020.100052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey Adam, L. et al. SARS-CoV-2 infects human engineered heart tissues and models COVID-19 myocarditis. JACC: Basic Transl. Sci. 6, 331&#x2013;345 (2021).</Citation></Reference><Reference><Citation>Klok, F. A. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145&#x2013;147 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32291094</ArticleId><ArticleId IdType="pmc">7146714</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2020.04.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Poissy, J. et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 142, 184&#x2013;186 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32330083</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047430</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong, X., Chi, J. &amp; Gao, Q. Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis. Thromb. J. 19, 32 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34011381</ArticleId><ArticleId IdType="pmc">8132033</ArticleId><ArticleId IdType="doi">10.1186/s12959-021-00284-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner, W. J. &amp; Gorog, D. A. Incidence of thrombotic complications in COVID-19: on behalf of ICODE: The International COVID-19 Thrombosis Biomarkers Colloquium. J. Thromb. Thrombolysis 52, 999&#x2013;1006 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34047938</ArticleId><ArticleId IdType="pmc">8161345</ArticleId><ArticleId IdType="doi">10.1007/s11239-021-02475-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L. et al. D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J. Thromb. Haemost. 18, 1324&#x2013;1329 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32306492</ArticleId><ArticleId IdType="doi">10.1111/jth.14859</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi, G. &amp; Favaloro, E. J. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis. Thromb. Haemost. 120, 876&#x2013;878 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32246450</ArticleId><ArticleId IdType="pmc">7295300</ArticleId><ArticleId IdType="doi">10.1055/s-0040-1709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis and angiogenesis in COVID-19. N. Engl. J. Med. 383, 120&#x2013;128 (2020). Postmortem analysis of lungs from patients who died of COVID-19 or of influenza A (H1N1), showing diffuse alveolar damage with perivascular T cell infiltration in both cases, but distinctive features in COVID-19 only, consisting of severe endothelial injury, widespread thrombosis and microangiopathy.</Citation><ArticleIdList><ArticleId IdType="pubmed">32437596</ArticleId><ArticleId IdType="pmc">7412750</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussani, R. et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. Lancet EBioMedicine 61, 103104 (2020). Postmortem pathological analysis in 41 consecutive patients who died of COVID-19 in Italy, showing COVID-19-specific features in the lungs, such as thrombosis of the microvasculature and macrovasculature and several dysmorphic pneumocytes; no virus-related alterations were found in other organs.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.103104</ArticleId></ArticleIdList></Reference><Reference><Citation>Carsana, L. et al. Pulmonary postmortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect. Dis. 20, 1135&#x2013;1140 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32526193</ArticleId><ArticleId IdType="pmc">7279758</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(20)30434-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox, S. E. et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir. Med. 8, 681&#x2013;686 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32473124</ArticleId><ArticleId IdType="pmc">7255143</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(20)30243-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Buja, L. M. et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc. Pathol. 48, 107233 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32434133</ArticleId><ArticleId IdType="pmc">7204762</ArticleId><ArticleId IdType="doi">10.1016/j.carpath.2020.107233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann. Intern. Med. 173, 268&#x2013;277 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32374815</ArticleId><ArticleId IdType="doi">10.7326/M20-2003</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle, D., O&#x2019;Donnell, J. S., Sharif, K., Emery, P. &amp; Bridgewood, C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2, e437&#x2013;e445 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32835247</ArticleId><ArticleId IdType="pmc">7252093</ArticleId><ArticleId IdType="doi">10.1016/S2665-9913(20)30121-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannis, D., Ziogas, I. A. &amp; Gianni, P. Coagulation disorders in coronavirus-infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin. Virol. 127, 104362 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32305883</ArticleId><ArticleId IdType="pmc">7195278</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2020.104362</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman, N., Antoniak, S., Wolberg, A. S., Kasthuri, R. &amp; Key, N. S. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler. Thromb. Vasc. Biol. 40, 2033&#x2013;2044 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32657623</ArticleId><ArticleId IdType="pmc">7447001</ArticleId><ArticleId IdType="doi">10.1161/ATVBAHA.120.314514</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417&#x2013;1418 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32325026</ArticleId><ArticleId IdType="pmc">7172722</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua, G. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 7, e575&#x2013;e582 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32619411</ArticleId><ArticleId IdType="pmc">7326446</ArticleId><ArticleId IdType="doi">10.1016/S2352-3026(20)30216-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Aid, M. et al. Vascular disease and thrombosis in SARS-CoV-2-infected rhesus macaques. Cell 183, 1354&#x2013;1366 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33065030</ArticleId><ArticleId IdType="pmc">7546181</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.10.005</ArticleId></ArticleIdList></Reference><Reference><Citation>McKechnie, J. L. &amp; Blish, C. A. The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell Host Microbe 27, 863&#x2013;869 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32464098</ArticleId><ArticleId IdType="pmc">7237895</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2020.05.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Z. et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883&#x2013;890 (2020). Results from a meta-transcriptomic profiling study from the bronchoalveolar lavage fluid of eight patients with COVID-19, showing marked upregulation of pro-inflammatory cytokines and robust activation of numerous interferon stimulated genes.</Citation><ArticleIdList><ArticleId IdType="pubmed">32407669</ArticleId><ArticleId IdType="pmc">7196896</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497&#x2013;506 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId><ArticleId IdType="pmc">7159299</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036&#x2013;1045 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32416070</ArticleId><ArticleId IdType="pmc">7227586</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620&#x2013;2629 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32217835</ArticleId><ArticleId IdType="pmc">7190990</ArticleId><ArticleId IdType="doi">10.1172/JCI137244</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann, B. &amp; Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34&#x2013;45 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23222502</ArticleId><ArticleId IdType="doi">10.1038/nri3345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319&#x2013;329 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33824483</ArticleId><ArticleId IdType="pmc">8023349</ArticleId><ArticleId IdType="doi">10.1038/s41577-021-00536-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark, K. &amp; Massberg, S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat. Rev. Cardiol. 18, 666&#x2013;682 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33958774</ArticleId><ArticleId IdType="pmc">8100938</ArticleId><ArticleId IdType="doi">10.1038/s41569-021-00552-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. JCI Insight https://doi.org/10.1172/jci.insight.138999 (2020).</Citation></Reference><Reference><Citation>Barnes, B. J. et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J. Exp. Med. 217, 20200652 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200652</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 12, eabd3876 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33139519</ArticleId><ArticleId IdType="pmc">7724273</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384, 2092&#x2013;2101 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33835769</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz, N. H. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2124&#x2013;2130 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33835768</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2104882</ArticleId></ArticleIdList></Reference><Reference><Citation>Arepally, G. M. &amp; Ortel, T. L. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood 138, 293&#x2013;298 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34323940</ArticleId><ArticleId IdType="pmc">8172307</ArticleId><ArticleId IdType="doi">10.1182/blood.2021012152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard, I., Limonta, D., Mahal, L. K. &amp; Hobman, T. C. Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19. Viruses https://doi.org/10.3390/v13010029 (2020).</Citation></Reference><Reference><Citation>Lovren, F. et al. Angiotensin-converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 295, H1377&#x2013;H1384 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18660448</ArticleId><ArticleId IdType="doi">10.1152/ajpheart.00331.2008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautista-Vargas, M., Bonilla-Abadia, F. &amp; Canas, C. A. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19. J. Thromb. Thrombolysis 50, 479&#x2013;483 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32519164</ArticleId><ArticleId IdType="doi">10.1007/s11239-020-02172-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Canzano, P. et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl. Sci. 6, 202&#x2013;218 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33649738</ArticleId><ArticleId IdType="pmc">7904280</ArticleId><ArticleId IdType="doi">10.1016/j.jacbts.2020.12.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosell, A. et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality-brief report. Arterioscler. Thromb. Vasc. Biol. 41, 878&#x2013;882 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33267656</ArticleId><ArticleId IdType="doi">10.1161/ATVBAHA.120.315547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi, G., Plebani, M. &amp; Henry, B. M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin. Chim. Acta 506, 145&#x2013;148 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32178975</ArticleId><ArticleId IdType="pmc">7102663</ArticleId><ArticleId IdType="doi">10.1016/j.cca.2020.03.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli, B. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy and follow-up. J. Am. Coll. Cardiol. 75, 2950&#x2013;2973 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32311448</ArticleId><ArticleId IdType="pmc">7164881</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary, R. et al. Thromboinflammatory biomarkers in COVID-19: systematic review and meta-analysis of 17,052 patients. Mayo Clin. Proc. Innov. Qual. Outcomes 5, 388&#x2013;402 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33585800</ArticleId><ArticleId IdType="pmc">7869679</ArticleId><ArticleId IdType="doi">10.1016/j.mayocpiqo.2021.01.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdivia-Mazeyra, M. F. et al. Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature. Virchows Arch. 478, 487&#x2013;496 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32915265</ArticleId><ArticleId IdType="doi">10.1007/s00428-020-02926-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaid, Y. et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ. Res. 127, 1404&#x2013;1418 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">7641188</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317703</ArticleId></ArticleIdList></Reference><Reference><Citation>Manne, B. K. et al. Platelet gene expression and function in patients with COVID-19. Blood 136, 1317&#x2013;1329 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32573711</ArticleId><ArticleId IdType="doi">10.1182/blood.2020007214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongiovanni, D. et al. SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype. Cell Death Dis. 12, 50 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33414384</ArticleId><ArticleId IdType="pmc">7790351</ArticleId><ArticleId IdType="doi">10.1038/s41419-020-03333-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Gragnano, F. et al. The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. Mediators Inflamm. 2017, 5620314 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28634421</ArticleId><ArticleId IdType="pmc">5467347</ArticleId><ArticleId IdType="doi">10.1155/2017/5620314</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikawa, M. et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19. Nat. Commun. 12, 7135 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34887400</ArticleId><ArticleId IdType="pmc">8660840</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-27378-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga, L. et al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature 594, 88&#x2013;93 (2021). The study reports high-throughput screening of over 3,000 clinically approved drugs for small molecules that inhibit cell&#x2013;cell fusion induced by the SARS-CoV-2 spike protein; a mechanism for cell fusion based on the activation of the cellular scramblase TMEM16F and a drug (niclosamide) that blocks this effect are identified.</Citation><ArticleIdList><ArticleId IdType="pubmed">33827113</ArticleId><ArticleId IdType="pmc">7611055</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03491-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, H. et al. TMEM16F forms a Ca<sup>2+</sup>-activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell 151, 111&#x2013;122 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23021219</ArticleId><ArticleId IdType="pmc">3582364</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2012.07.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig, A. A. et al. TMEM16F-mediated platelet membrane phospholipid scrambling is critical for hemostasis and thrombosis but not thromboinflammation in mice. Arterioscler. Thromb. Vasc. Biol. 36, 2152&#x2013;2157 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27634832</ArticleId><ArticleId IdType="doi">10.1161/ATVBAHA.116.307727</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii, T., Sakata, A., Nishimura, S., Eto, K. &amp; Nagata, S. TMEM16F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets. Proc. Natl Acad. Sci. USA 112, 12800&#x2013;12805 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26417084</ArticleId><ArticleId IdType="pmc">4611630</ArticleId><ArticleId IdType="doi">10.1073/pnas.1516594112</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelletto, A. et al. SARS-CoV-2 spike protein activates TMEM16F-mediated platelet procoagulant activity. Preprint at bioRxiv https://doi.org/10.1101/2021.1112.1114.472668 (2021).</Citation></Reference><Reference><Citation>Wagner, K. U. et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 127, 4949&#x2013;4958 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11044408</ArticleId><ArticleId IdType="doi">10.1242/dev.127.22.4949</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter, J. C. et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl Acad. Sci. USA 117, 25018&#x2013;25025 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32943538</ArticleId><ArticleId IdType="pmc">7547220</ArticleId><ArticleId IdType="doi">10.1073/pnas.2010540117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, L. et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci. Immunol. https://doi.org/10.1126/sciimmunol.abh2259 (2021).</Citation></Reference><Reference><Citation>Magro, C. et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl. Res. 220, 1&#x2013;13 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32299776</ArticleId><ArticleId IdType="pmc">7158248</ArticleId><ArticleId IdType="doi">10.1016/j.trsl.2020.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, J. et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 136, 2080&#x2013;2089 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32877502</ArticleId><ArticleId IdType="doi">10.1182/blood.2020008248</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, T. et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. Preprint at medRxiv https://doi.org/10.1101/2020.1103.1129.20041962 (2020).</Citation></Reference><Reference><Citation>Viner, R. M. et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 175, 143&#x2013;156 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32975552</ArticleId><ArticleId IdType="doi">10.1001/jamapediatrics.2020.4573</ArticleId></ArticleIdList></Reference><Reference><Citation>Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N. &amp; Theocharis, P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395, 1607&#x2013;1608 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32386565</ArticleId><ArticleId IdType="pmc">7204765</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)31094-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker, E. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 324, 259&#x2013;269 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32511692</ArticleId><ArticleId IdType="pmc">7281356</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.10369</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsaied, T. et al. Review of cardiac involvement in multisystem inflammatory syndrome in children. Circulation 143, 78&#x2013;88 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33166178</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049836</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter, M. J., Shankar-Hari, M. &amp; Tibby, S. M. Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection: an overview. Intensive Care Med. 47, 90&#x2013;93 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33057783</ArticleId><ArticleId IdType="doi">10.1007/s00134-020-06273-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603&#x2013;2615 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33301246</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403&#x2013;416 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33378609</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99&#x2013;111 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33306989</ArticleId><ArticleId IdType="pmc">7723445</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda, N. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N. Engl. J. Med. 385, 1078&#x2013;1090 (2021). Data analysis from a vaccination programme in Israel (over 880,000 individuals) with the BNT162b2 mRNA vaccine shows that vaccination was associated with an excess risk of myocarditis (2.7 events per 100,000 persons), which was significantly lower than after natural SARS-CoV-2 infection.</Citation><ArticleIdList><ArticleId IdType="pubmed">34432976</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2110475</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevorach, D. et al. Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N. Engl. J. Med. 385, 2140&#x2013;2149 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34614328</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2109730</ArticleId></ArticleIdList></Reference><Reference><Citation>Witberg, G. et al. Myocarditis after COVID-19 vaccination in a large healthcare organization. N. Engl. J. Med. 385, 2132&#x2013;2139 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34614329</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2110737</ArticleId></ArticleIdList></Reference><Reference><Citation>Shay, D. K., Shimabukuro, T. T. &amp; DeStefano, F. Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2021.2821 (2021).</Citation></Reference><Reference><Citation>Bozkurt, B., Kamat, I. &amp; Hotez, P. J. Myocarditis with COVID-19 mRNA vaccines. Circulation 144, 471&#x2013;484 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34281357</ArticleId><ArticleId IdType="pmc">8340726</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson, K. F. et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation 144, 506&#x2013;508 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34133884</ArticleId><ArticleId IdType="pmc">8340725</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.055913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosner, C. M. et al. Myocarditis temporally associated with COVID-19 vaccination. Circulation 144, 502&#x2013;505 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34133885</ArticleId><ArticleId IdType="pmc">8340723</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.055891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko, K., Buckstein, M., Ni, H. &amp; Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165&#x2013;175 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16111635</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Caso, F. et al. Could SARS-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun. Rev. 19, 102524 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32220633</ArticleId><ArticleId IdType="pmc">7271072</ArticleId><ArticleId IdType="doi">10.1016/j.autrev.2020.102524</ArticleId></ArticleIdList></Reference><Reference><Citation>Caforio, A. L., Mahon, N. J., Tona, F. &amp; McKenna, W. J. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur. J. Heart Fail. 4, 411&#x2013;417 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12167378</ArticleId><ArticleId IdType="doi">10.1016/S1388-9842(02)00010-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani, A. &amp; Kharrazian, D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. 217, 108480 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32461193</ArticleId><ArticleId IdType="pmc">7246018</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2020.108480</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook, H., Raza, S., Nowell, J., Young, M. &amp; Edison, P. Long COVID mechanisms, risk factors and management. BMJ 374, n1648 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson, M. et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep. 3, 573&#x2013;580 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33723532</ArticleId><ArticleId IdType="pmc">7946344</ArticleId><ArticleId IdType="doi">10.1016/j.jaccas.2021.01.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni, C. et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat. Med. 26, 1037&#x2013;1040 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32393804</ArticleId><ArticleId IdType="pmc">7751267</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0916-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626&#x2013;631 (2021). Analysis of data from self-reported symptoms in the COVID Symptom Study app to understand symptoms associated with the development of long COVID. Experiencing more than five symptoms during the first week of illness was associated with long COVID. Long COVID was also characterized by fatigue, headache, dyspnea and anosmia and was more likely with increasing age and body mass index and female sex.</Citation><ArticleIdList><ArticleId IdType="pubmed">33692530</ArticleId><ArticleId IdType="pmc">7611399</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans, R. A. et al. Physical, cognitive and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir. Med. https://doi.org/10.1016/S2213-2600(21)00383-0 (2021).</Citation></Reference><Reference><Citation>Sigfrid, L. et al. Long COVID in adults discharged from UK hospitals after COVID-19: a prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Reg. Health Eur. 8, 100186 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34386785</ArticleId><ArticleId IdType="pmc">8343377</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpal, S. et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 6, 116&#x2013;118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32915194</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark, D. E. et al. COVID-19 myocardial pathology evaluation in athletes with cardiac magnetic resonance (COMPETE CMR). Circulation 143, 609&#x2013;612 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33332151</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.052573</ArticleId></ArticleIdList></Reference><Reference><Citation>Shou, S. et al. Animal models for COVID-19: hamsters, mouse, ferret, mink, tree shrew and non-human primates. Front. Microbiol. 12, 626553 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34531831</ArticleId><ArticleId IdType="pmc">8438334</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2021.626553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, C. Y. &amp; Lowen, A. C. Animal models for SARS-CoV-2. Curr. Opin. Virol. 48, 73&#x2013;81 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33906125</ArticleId><ArticleId IdType="pmc">8023231</ArticleId><ArticleId IdType="doi">10.1016/j.coviro.2021.03.009</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>